Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer

16 novembre 2026 aggiornato da: Lee, Soo Hyeon, Korea University Anam Hospital

A Phase 2, Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Erlotinib in Patients With EGFR-Amplified Metastatic Colorectal Cancer Who Have Failed or Are Not Eligible for Oxaliplatin- and Irinotecan-Based Chemotherapy

This phase II, open-label, single-arm clinical trial is designed to evaluate the efficacy and safety of a combination therapy with bevacizumab and erlotinib as a salvage treatment in patients with metastatic colorectal cancer who have failed or are intolerant to standard oxaliplatin- and irinotecan-based chemotherapy, and whose tumors harbor an EGFR copy number gain of 4 or higher confirmed by NGS testing. The primary objective is to evaluate progression-free survival (PFS), and secondary objectives include objective response rate (ORR), overall survival (OS), disease control rate (DCR), safety, and quality of life.

Panoramica dello studio

Stato

Non ancora reclutamento

Descrizione dettagliata

This study investigates the clinical benefit of combining an anti-VEGF agent (bevacizumab) with an EGFR tyrosine kinase inhibitor (erlotinib) in refractory metastatic colorectal cancer with EGFR amplification. Eligible patients will receive bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral erlotinib at 150 mg. Tumor assessments will be conducted periodically using RECIST version 1.1 to determine clinical outcomes, and toxicities will be graded according to NCI CTCAE version 5.0.

Tipo di studio

Interventistico

Iscrizione (Stimato)

39

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

19 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Histologically or cytologically proven metastatic/recurrent colorectal cancer who have failed or are intolerant to standard chemotherapy based on oxaliplatin and irinotecan (and if RAS wild-type, an anti-EGFR therapy).

  2. EGFR copy number gain ≥ 4 confirmed by NGS testing performed at the participating institution.

  3. Measurable disease per RECIST version 1.1 (measurable lesions are not mandatory for study entry).

  4. Age ≥ 19 years.

  5. ECOG performance status 0-2.

  6. Adequate bone marrow and organ function:

    • Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L
    • Hemoglobin (Hgb) ≥ 9.0 g/dL
    • Platelet count ≥ 75 x 10^9/L
    • Serum creatinine ≤ 1.5 x ULN or creatinine clearance > 30 mL/min
    • Total bilirubin ≤ 2.0 x ULN (subjects with biliary obstruction are eligible if criteria are met after appropriate biliary drainage)
    • AST and ALT ≤ 3 x ULN (or ≤ 5 x ULN if liver metastases are present)
  7. Adequate cardiac function: QTc ≤ 480 msec (if QTc > 480 msec, average QTc < 480 msec in triplicate measurements).

  8. Ability to swallow oral medication.

  9. Negative serum β-HCG pregnancy test within 14 days prior to study drug administration for female patients of childbearing potential.

  10. Agreement to use appropriate contraception methods as outlined in the protocol.

  11. Life expectancy ≥ 3 months.

  12. Signed and dated informed consent prior to any study-related procedures.

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Prior history of combination therapy with an EGFR tyrosine kinase inhibitor and anti-VEGF blockade.
  3. Known hypersensitivity to the study drug components.
  4. Cytotoxic chemotherapy within 14 days, investigational drugs within 2 weeks or 5 half-lives, or monoclonal antibody therapy within 4 weeks prior to study entry.
  5. Uncontrolled severe infection.
  6. Severe medical or psychiatric conditions including active cardiac disease, uncontrolled hypertension, significant arrhythmias, or conditions prolonging QTc.
  7. Active central nervous system (CNS) metastases (unless radiologically stable, asymptomatic, and off steroids for at least 4 weeks; leptomeningeal disease is excluded).
  8. History of another primary malignancy (except adequately treated non-melanoma skin cancer, superficial cervical carcinoma, stage 1 bladder cancer, completely resected thyroid cancer, or other solid tumors with no evidence of recurrence for at least 36 months).
  9. Persistence of toxicities from prior anticancer therapy > Grade 1 (except alopecia).
  10. Extensive radiotherapy to the bone marrow within 4 weeks or limited radiotherapy within 2 weeks prior to study entry.
  11. Major surgery within 4 weeks prior to study entry or unrecovered from surgical side effects.
  12. Thrombotic or thromboembolic events within 6 months.
  13. History or evidence of bleeding disorders.
  14. Therapeutic use of maximum dose anticoagulants.
  15. Unhealed wounds, acute ulcers, or bone fractures.
  16. Abdominal fistula, gastrointestinal perforation, or active GI bleeding within 6 months.
  17. Urine dipstick protein ≥ 2+ with 24-hour urine protein > 1g.
  18. History or pathological findings of major GI surgery that may impair oral absorption.
  19. Evidence of active infection including Hepatitis B, Hepatitis C, or HIV (subjects with controlled or inactive HBV/HCV under specific protocol criteria are permitted).
  20. Conditions or diseases deemed by the investigator to contraindicate study participation.
  21. Medical, psychological, cognitive, or other conditions that impair the subject's ability to understand, consent, or comply with protocol procedures.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Bevacizumab plus Erlotinib

Participants will receive Bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral Erlotinib at 150 mg.

Administered at 7.5 mg/kg intravenously every 3 weeks.

Altri nomi:
  • Onbevzi

Administered at 150 mg orally daily.

Altri nomi:
  • Eltinib

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-Free Survival (PFS)
Lasso di tempo: From the first dose of study treatment until disease progression or death, assessed up to 12 months

PFS is calculated from the date of the first administration of the study drug to the date of documented disease progression or death from any cause.

From the first dose of study treatment until disease progression or death, assessed up to 12 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Objective Response Rate (ORR)
Lasso di tempo: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months

Proportion of patients who achieve a Complete Response (CR) or Partial Response (PR) evaluated using RECIST version 1.1.

Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
Overall Survival (OS)
Lasso di tempo: From the first dose of study treatment until death, assessed up to 1 year of survival follow-up

OS is calculated from the date of the first administration of the study drug to the date of death from any cause or the last follow-up date

From the first dose of study treatment until death, assessed up to 1 year of survival follow-up
Disease Control Rate (DCR)
Lasso di tempo: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months

Proportion of patients who achieve CR, PR, or stable disease (SD) maintained for at least 6 weeks after study drug administration

Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
Duration of Response (DOR)
Lasso di tempo: From initial response until documented disease progression, assessed up to approximately 12 months

Calculated from the time initial response (CR or PR) is documented until the date of progressive disease

From initial response until documented disease progression, assessed up to approximately 12 months
Time to Response (TTR)
Lasso di tempo: From the first dose of study treatment until the first documented response, assessed up to approximately 12 months

Calculated from the first dose of study treatment to the date of initial response (CR or PR)

From the first dose of study treatment until the first documented response, assessed up to approximately 12 months
Safety and Tolerability
Lasso di tempo: From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months

Evaluated by type, frequency, and severity of adverse events graded according to NCI CTCAE version 5.0

From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months
Quality of Life (QoL) EORTC QLQ-C30
Lasso di tempo: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months
Quality of Life (QoL) CR26
Lasso di tempo: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (CR26)

Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

4 gennaio 2027

Completamento primario (Stimato)

31 gennaio 2028

Completamento dello studio (Stimato)

31 gennaio 2030

Date di iscrizione allo studio

Primo inviato

10 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

16 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Yes. De-identified individual participant data underlying the results reported in this article, after de-identification, will be shared beginning 3 months and ending 5 years following article publication to researchers who provide a methodologically sound proposal. Proposals should be directed to the corresponding author. Data getters will be required to sign a data access agreement.

Periodo di condivisione IPD

Beginning 3 months and ending 5 years following article publication.

Criteri di accesso alla condivisione IPD

De-identified individual participant data will be shared with researchers who provide a methodologically sound proposal to achieve the aims of the approved proposal. Proposals should be directed to the corresponding author. Data requesters will be required to sign a data access agreement.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi